p70S6K
p70S6K, encoded within the S6K1/RPS6KB1 axis, regulates protein synthesis and cell growth by phosphorylating ribosomal protein S6 after mitogen stimulation[1]. Mechanistically, PI3K/Akt/mTOR signaling activates p70S6K through ordered Ser/Thr phosphorylation, and mTOR-S6K1 dynamics on the eIF3 translation initiation complex connect growth signals to translational control[1][2][3]. In cancer models, enhanced p70S6K expression or activation correlates with poor prognosis and supports epithelial-mesenchymal transition, cancer stemness, and drug resistance[1]. Compared with related isoforms, p85S6K1 contains 23 additional N-terminal amino acids, whereas p70S6K1 is the shorter S6K1 isoform studied mainly in cytoplasmic signaling contexts[5][6]. For experimental applications, rapamycin blocks phosphorylation and activation of 70-kDa S6 kinases, while PF-4708671 provides a cell-permeable S6K1-selective inhibitor for dissecting p70S6K-dependent signaling[4][7].
References:
- [1]. Artemenko M, et al. p70 S6 kinase as a therapeutic target in cancers: More than just an mTOR effector. Cancer Lett. 2022 Jun 1;535:215593. [Content Brief]
- [2]. Holz MK, et al. mTOR and S6K1 mediate assembly of the translation preinitiation complex through dynamic protein interchange and ordered phosphorylation events. Cell. 2005 Nov 18;123(4):569-80. [Content Brief]
- [3]. Chung J, et al. PDGF- and insulin-dependent pp70S6k activation mediated by phosphatidylinositol-3-OH kinase. Nature. 1994 Jul 7;370(6484):71-5. [Content Brief]
- [4]. Chung J, et al. Rapamycin-FKBP specifically blocks growth-dependent activation of and signaling by the 70 kd S6 protein kinases. Cell. 1992 Jun 26;69(7):1227-36. [Content Brief]
- [5]. Grove JR, et al. Cloning and expression of two human p70 S6 kinase polypeptides differing only at their amino termini. Mol Cell Biol. 1991;11(11):5541-5550.
- [6]. Kim D, et al. Regulation and localization of ribosomal protein S6 kinase 1 isoforms. Growth Factors. 2009 Feb;27(1):12-21. [Content Brief]
- [7]. Pearce LR, et al. Characterization of PF-4708671, a novel and highly specific inhibitor of p70 ribosomal S6 kinase (S6K1). Biochem J. 2010 Oct 15;431(2):245-55. [Content Brief]
All Product Categories
-
p70S6K Related Products (24)
Related Products (24)
-
Antibodies (2)
- 1
- 2
-
Sapanisertib
0 ImagesSynonyms: INK-128; MLN0128; TAK-228Sapanisertib (INK-128; MLN0128; TAK-228) is an orally active dual mTORC1/mTORC2 inhibitor. Sapanisertib directly and simultaneously inhibits mTORC1/2 activity through competitive binding with ATP, thereby comprehensively blocking downstream processes such as protein and lipid synthesis and cytoskeletal reorganization, consequently suppressing tumor cell proliferation and promoting apoptosis. Sapanisertib is applicable to research on melanoma, ovarian cancer, pulmonary fibrosis, and hematological malignancies.
-
PF-4708671
0 ImagesPF-4708671 is a potent cell-permeable S6K1 inhibitor with a Ki of 20 nM and IC50 of 160 nM.
-
308-R
0 ImagesCat. No.: HY-151009CAS No.: 2376724-98-8308-R is a SGK3/SGK1/S6K1 inhibitor. 308-R exhibits an IC50 of 5 nM against human SGK3, an IC50 of 10 nM against human SGK1, and an IC50 of 1 nM against human S6K1. 308-R can be used in breast cancer research. It is also applicable to studies related to PROTAC synthesis, such as serving as the target protein ligand for PROTAC SGK3 degrader-2 (HY-176823).
-
CKI-7 free base
0 ImagesCKI-7 free base is a potent and ATP-competitive casein kinase 1 (CK1) inhibitor with an IC50 of 6 μM and a Ki of 8.5 μM. CKI-7 free base is a selective Cdc7 kinase inhibitor. CKI-7 free base also inhibits SGK, ribosomal S6 kinase-1 (S6K1) and mitogen- and stress-activated protein kinase-1 (MSK1). CKI-7 free base has a much weaker effect on casein kinase II and other protein kinases.
-
CKI-7
0 ImagesCKI-7 is a potent and ATP-competitive casein kinase 1 (CK1) inhibitor with an IC50 of 6 μM and a Ki of 8.5 μM. CKI-7 is a selective Cdc7 kinase inhibitor. CKI-7 also inhibits SGK, ribosomal S6 kinase-1 (S6K1) and mitogen- and stress-activated protein kinase-1 (MSK1). CKI-7 has a much weaker effect on casein kinase II and other protein kinases.
-
Eudesmin
0 ImagesSynonyms: (-)-Eudesmin; Eudesmine; (-)-EudesmineEudesmin ((-)-Eudesmin) impairs adipogenic differentiation via inhibition of S6K1 signaling pathway. Eudesmin possesses diverse therapeutic effects, including anti-tumor, anti-inflammatory, and anti-bacterial activities.
-
LY-2584702 free base
0 ImagesCat. No.: HY-12493CAS No.: 1082949-67-4LY-2584702 free base is a selective ATP competitive inhibitor of p70S6K with an IC50 of 4 nM. In S6K1 enzyme assay, the IC50 of LY-2584702 is 2 nM.
-
Hu7691 free base
0 ImagesCat. No.: HY-132302ACAS No.: 2241232-43-7
-
HSND80
0 ImagesCat. No.: HY-172392HSND80 (Compound 1) is an orally active inhibitor of MNK/p70S6K, with Kd values of 44 nM against MNK1 and 4 nM against MNK2. HSND80 has a longer target residence time of 45 mins and 58 mins against MNK1 and MNK2 respectively. HSND80 can suppress non-small cell lung cancer (NSCLC) both in vitro and in vivo, and suppress Triple-Negative Breast Cancer (TNBC) in vitro.
-
DD1
0 ImagesDD1, a proteasome inhibitor, targets Bax activation and P70S6K degradation during acute myeloid leukemia (AML) apoptosis. DD1 induces apoptosis in the caspase-dependent manner. DD1 induces mitochondrial membrane depolarization and Bad dephosphorylation.
- 1
- 2
